The long-called-for restructuring of the UK biotech sector looked to have taken a major step last week when Cambridge Antibody Technology Group plc said it would acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$179.8 million). (BioWorld International)